Albumin-conjugated paclitaxel (Abraxane®), which was approved by the FDA for treating metastatic breast, non-small-cell lung, and pancreatic cancers, is expected to be effectively taken up by hypoxic HCC cells. The gene discussed is ALB; the disease is hepatocellular carcinoma.